Puma Biotechnology, Inc.
PBYI Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$10.85
KIRA · Stoqly’s AI analyst, in plain words
- Puma Biotechnology, Inc. had $228M of revenue in fiscal 2025, down 0.9% on the year before. Over five years, revenue changed +0.3% a year on average.
- Its operating margin was 16.3%, up 2.9 pts: of every 100 in sales, about 16 is left after running the business.
- Puma Biotechnology, Inc. made $31.1M of net profit in fiscal 2025.
- Free cash flow was $41.7M in fiscal 2025, 18.3% of revenue.
- Puma Biotechnology, Inc. has $74.9M more cash than debt.
Market cap
$571M
P/E
20.9x
Revenue
$228M
Net income
$31.1M
Free cash flow
$41.7M
Operating margin
16.3%
Puma Biotechnology, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−0.9%
No. Sales fell 0.9% last year.
Does it make a profit?
13.6%
Yes. It keeps 13.6% of every sale as profit.
Does profit turn into cash?
18.3%
Yes. 18.3% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
20.9x
One share costs 20.9 times its yearly profit per share.
What Puma Biotechnology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- PUMA BIOTECHNOLOGY, INC.
- CIK
- 0001401667
Puma Biotechnology, Inc. · PBYI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $253M | $228M | $236M | $230M | $228M |
| Revenue growth | 12.5% | −9.9% | 3.3% | −2.2% | −0.9% |
| Gross margin | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% |
| Operating margin | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% |
| Net income | −$29.1M | $0.0M | $21.6M | $30.3M | $31.1M |
| Net margin | −11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
| Diluted EPS | −$0.72 | $0.00 | $0.45 | $0.62 | $0.61 |
| Cash | |||||
| Cash from operations | $20.7M | −$15.8M | $27.0M | $38.9M | $41.8M |
| Capital expenditure | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M |
| Free cash flow | $20.7M | −$15.8M | $26.9M | $38.9M | $41.7M |
| FCF margin | 8.2% | −6.9% | 11.4% | 16.9% | 18.3% |
| Share count change | 2.7% | 10.6% | 5.8% | 3.3% | 3.2% |
| Debt and strength | |||||
| Cash and short-term investments | $82.1M | $81.1M | $95.9M | $101M | $97.5M |
| Debt incl. finance leases | $102M | $102M | $102M | $68.0M | $22.7M |
| Shareholders' equity | −$2.4M | $21.6M | $53.4M | $92.1M | $130M |
| Net debt / EBITDA | 1.6x | 0.6x | 0.1x | −0.8x | −1.6x |
| Current ratio | 1.3x | 1.7x | 1.6x | 1.5x | 2.0x |
| Interest coverage | 0.1x | 2.0x | 2.4x | 2.5x | 5.6x |
| Returns and quality | |||||
| Return on capital | 5.8% | 36.2% | 52.2% | 52.3% | 58.4% |
| Return on equity | — | 0.0% | 57.5% | 41.6% | 28.0% |
| Return on tangible equity | — | — | — | 73.9% | 35.0% |
| Piotroski F-score | 4 | 4 | 5 | 6 | 7 |
| Altman Z'' | −18.8 | −17.6 | −16.1 | −16.7 | −14.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.1M
10 insiders
Of sales under plans
95%
$2.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Puma Biotechnology, Inc. · PBYI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.85 a share, the company is worth $571M: 20.9 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001401667). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.